Key result
Cabozantinib increased the risk of developing all-grade hypertension in cancer patients compared with controls.
Why the study?
Does cabozantinib increase the risk of hypertension in cancer patients?
Meta-Analysis (n=1,514)
Does cabozantinib increase the risk of hypertension in cancer patients?
Cabozantinib treatment in cancer patients is associated with a significantly increased risk of developing all-grade and high-grade hypertension.
Answers are grounded in this paper and cite their sources.
Requires BP monitoring with cabozantinib; confirms substantially elevated hypertension risk in cancer patients.
INTRODUCTION: Cabozantinib (XL184) is an oral inhibitor of multiplereceptor tyrosine kinases including mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2). Hypertension is one of its major side effects, but the incidence rate and overall risk has not been systematically studied. We thus conducted this meta-analysis to investigate the overall incidence and risk of developing hypertension in cancer patients treated with cabozantinib. AREAS COVERED: Pubmed, Embase and oncology conference proceedings were searched for relevant studies. Eligible studies were phase II and III prospective clinical trials of cabozantinib in cancer patients with data on hypertension available. A total of 1,514 patients (cabozantinib, 1083; control, 431) with a variety of solid tumors from 8 prospective clinical trials were included for the meta-analysis. The use of cabozantinib was associated with significantly increased risk of developing all grade (RR 5.48; 95%CI, 3.76-7.99; p < 0.001) and high grade (5.09; 95% CI: 2.71-9.54, p < 0.001) hypertension in comparison with controls. Additionally, the risk of high grade hypertension with cabozantinib was substantially higher than other four approved VEGFR-TKIs (sorafenib, sunitinib, vandetanib and pazopanib). Expert commentary: Cancer patients receiving cabozantinib have an increased risk of developing hypertension. Close monitoring and management of hypertension are recommended.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2016) conducted a meta-analysis in Solid tumors (n=1,514). Cabozantinib vs. Controls was evaluated on All grade hypertension (RR 5.48, 95% CI 3.76-7.99, p=< 0.001). Cabozantinib increased the risk of developing all-grade hypertension in cancer patients compared with controls.
Synapse has enriched 10 related papers. Consider them for comparative context: